Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Shares Issued (2020 - 2024)

SAB Biotherapeutics (SABS) has disclosed Shares Issued for 5 consecutive years, with -$3.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Shares Issued fell 100.06% year-over-year to -$3.0, compared with a TTM value of $20409.0 through Dec 2024, up 112.99%, and an annual FY2024 reading of $20409.0, up 112.99% over the prior year.
  • Shares Issued was -$3.0 for Q4 2024 at SAB Biotherapeutics, down from $20412.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $4.2 million in Q1 2021 and bottomed at -$4.2 million in Q4 2021.
  • Average Shares Issued over 5 years is $11559.3, with a median of $3846.0 recorded in 2023.
  • The sharpest move saw Shares Issued plummeted 16761.0% in 2021, then surged 526300.0% in 2023.
  • Year by year, Shares Issued stood at $25000.0 in 2020, then tumbled by 16761.0% to -$4.2 million in 2021, then skyrocketed by 100.0% to -$1.0 in 2022, then soared by 526300.0% to $5262.0 in 2023, then plummeted by 100.06% to -$3.0 in 2024.
  • Business Quant data shows Shares Issued for SABS at -$3.0 in Q4 2024, $20412.0 in Q1 2024, and $5262.0 in Q4 2023.